Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany.
Additional Group of Compounds and Enhanced Research Activities Added to Agreement
NAPA, Calif., June 8 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board OTC Bulletin Board
An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. : SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, announced a six year extension of existing rights under its agreement with the Czech Republic Institute of Experimental Botany to receive exclusive global licenses, for all applications, to any cytokinin cy·to·ki·nin
Any of a class of plant hormones that promote cell division and growth and delay the senescence of leaves.
cytokinin developed, in-licensed or otherwise acquired by the Institute and the right to co-exploit with the Institute any cytokinins that Senetek does not elect to in-license. Senetek also has a right of first refusal Right of First Refusal
In general, the right of a person or company to purchase something before the offering is made available to others.
For example, a football team may have the right of first refusal on a player's contract. before the Institute can license any of its non-cytokinin compounds to any third party for cosmeceutical or anti-aging dermatological applications. In addition, a new group of compounds, "supercytokin plus", has been added to the agreement. The Institute will also perform enhanced research activities in the areas of pre-selective assay, development of analytical methods, stability testing, large scale synthesis and molecular mechanism of action.
"We are very pleased to extend our exclusive agreement with the Institute of Experimental Botany," stated Frank J. Massino, Chairman and Chief Executive Officer of Senetek PLC. "Our two commercialized topical skincare products, Pyratine-6(TM) for photodamaged skin and Pyratine XR(TM) which, in a rosacea-specific study, demonstrated continual improvement for all of the major symptoms of rosacea, are based on compounds developed by the Institute. Sixteen additional compounds developed by the Institute for our exclusive use have shown positive activity related to indications with significant commercial potential. We look forward to obtaining new and advanced technology from the Institute over the next six years."
"Our relationship with Senetek has been excellent and has resulted in achieving the goal of successfully commercializing our research," stated Prof. Ing. Miroslav Strnad, DrSc., Executive Board Member of the Institute. "We look forward to the next six years and our continuing development of advanced technologies for dermatological therapeutics."
About Senetek PLC:
Senetek PLC (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). : SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin kinetin (kī`nətĭn), one of a group of chemically similar plant hormones, the cytokinins, that promote cell division. In some instances kinetin acts together with another hormone, indoleacetic acid, or auxin; in other cases it acts in , the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites:
http://www.senetekplc.com/ http://www.pyratine-6.com/ http://www.pyratinexr.com/ About The Institute of Experimental Botany
The Institute was created in 1962 from the Department of Plant Physiology and the Department of Phytopathology phytopathology /phy·to·pa·thol·o·gy/ (-pah-thol´ah-je) the pathology of plants. of the Institute of Biology The Institute of Biology (IoB) is a professional body for biologists, primarily those working in the United Kingdom. Membership currently stands around 14,000. It was founded in 1950, received a Royal Charter in 1979 and holds charitable status. of the Czechoslovak Academy of Sciences. In 1990, it was divided into two independent units, one of which became The Institute of Experimental Botany in Prague and Olomouc. The Institute is highly regarded in the fields of plant genetics, physiology and biotechnology, where its work has included investigation of plant DNA repair, hormonal and ecological control of plant growth and development, and the mechanisms of action of plant growth regulators. For more information, visit the Institute's website:
This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and . Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.
CONTACT: Company, William O'Kelly of Senetek PLC, +1-707-226-3900, ext. 102; or Media, Maggie Carr, firstname.lastname@example.org, or Michael Rogers, email@example.com, both of Michael Rogers Public Relations, +1-212-255-7210, ext. 22, both for Senetek PLC
Web Site: http://www.senetekplc.com/ http://www.pyratine-6.com/ http://www.pyratinexr.com/ http://www.ueb.cas.cz/